Guggenheim analyst Yatin Suneja reiterated a Buy rating and $280.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "Biogen delivered ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments